Research

A meta-analysis of phase-III trials shows that immunotherapy is more efficacious in liver cancer of viral origin than of nonviral origin

Researchers at IDIBAPS have led a study, published in the journal Gastroenterology, in which they analyzed the clinical trials published in the past 20 years on hepatocellular carcinoma (2000-2020) and showed that immunotherapy in liver cancer is less effective when the cause of the tumor is not linked to a viral infection.

Florian Castet and Josep Maria Llovet